V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

Rund 3.300 Mitarbeitende setzen sich bei Novartis Österreich gemeinsam dafür ein, das Leben von Patientinnen und Patienten zu verlängern und zu verbessern. Willst du dabei sein? Dann denke mit uns ...

April 26, 2023 Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities ...

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...

Sr. Spec. DDIT IES Cloud Engineering Regular, Full time Universal Hierarchy Node India +Alternative Locations Hyderabad (Office) Giu 05, 2025 Assoc. Dir. DDIT IES Cloud Engineering Regular, Full time ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...

Imagine performing research at a leading global pharmaceutical corporation while gaining practical experience and contributing to the search for new disease therapies. Through internship programs at ...

We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline focused on delivering transformative medicines to fight disease, ...

Meet the Novartis Board of Directors, responsible for the direction, strategy, and administration of this global pharmaceutical and biotech company.

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...